| scholarly article | Q13442814 |
| P356 | DOI | 10.1089/AID.1987.3.409 |
| P698 | PubMed publication ID | 2833917 |
| P50 | author | Kent J. Weinhold | Q109935303 |
| P2093 | author name string | Lyerly HK | |
| Matthews TJ | |||
| Langlois AJ | |||
| Petteway SR Jr | |||
| Reed DL | |||
| Ahearne PA | |||
| P2860 | cites work | Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS) | Q22242256 |
| P433 | issue | 4 | |
| P921 | main subject | HIV | Q15787 |
| antibody | Q79460 | ||
| P304 | page(s) | 409-422 | |
| P577 | publication date | 1987-01-01 | |
| P1433 | published in | AIDS Research and Human Retroviruses | Q4651880 |
| P1476 | title | Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. | |
| P478 | volume | 3 |
| Q36801560 | A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization |
| Q92153012 | AAV-delivered eCD4-Ig protects rhesus macaques from high-dose SIVmac239 challenges |
| Q28477736 | An inducible cell-cell fusion system with integrated ability to measure the efficiency and specificity of HIV-1 entry inhibitors |
| Q92058300 | Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects |
| Q30408097 | Antibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination Strategies |
| Q81488462 | Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand |
| Q34047226 | Antibody-dependent cellular cytotoxicity detects type- and strain-specific antigens among human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus SIVmac isolates |
| Q54263363 | Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cell-mediated cytotoxicity assay. |
| Q36048830 | B cell responses to HIV and the development of human monoclonal antibodies |
| Q36687749 | Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses |
| Q41706173 | Broadly Reactive Antibody-Dependent Cellular Cytotoxic Response to HIV-1 Envelope Glycoproteins Precedes Broad Neutralizing Response in Human Infection |
| Q41411324 | CD3+, CD56+ non-MHC restricted cytotoxic T lymphocytes in two fraternal AIDS patients: a case report |
| Q29026902 | CD4 depletion in HIV-infected haemophilia patients is associated with rapid clearance of immune complex-coated CD4+ lymphocytes |
| Q35205365 | Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity. |
| Q67899864 | Cellular and humoral antigenic epitopes in HIV and SIV |
| Q24645399 | Characterizing the anti-HIV activity of papuamide A |
| Q37456637 | Complement and antibodies: a dangerous liaison in HIV infection? |
| Q41610618 | Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains |
| Q26782237 | Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1 |
| Q37347813 | Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. |
| Q33997891 | Deficient antibody-dependent cellular cytotoxicity against human immunodeficiency virus (HIV)-expressing target cells in perinatal HIV infection |
| Q36479067 | Development of IgG Mediated Antibody Dependent Cell-mediated Cytotoxicity (ADCC) in the Serum and Genital Mucosa of HIV Seroconverters |
| Q40054175 | Development of an epitope-based HIV-1 vaccine strategy from HIV-1 lipopeptide to dendritic-based vaccines |
| Q77481938 | Effect of interleukin (IL)-12 and IL-15 on activated natural killer (ANK) and antibody-dependent cellular cytotoxicity (ADCC) in HIV infection |
| Q37426168 | Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses |
| Q42061431 | Expression of human immunodeficiency virus genes using baculovirus expression system |
| Q61806778 | Expression of ligands for activating natural killer cell receptors on cell lines commonly used to assess natural killer cell function |
| Q33899181 | Fc receptor-mediated antiviral antibodies |
| Q42257677 | Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention |
| Q41741684 | Functions of Antibodies. |
| Q44358472 | HIV vaccine therapy |
| Q36674581 | HIV-Specific Treatment |
| Q36827554 | Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins |
| Q35315868 | Humoral immune responses in human HIV-1 infection clearance of initial burst of virus replication and protection against disease progression |
| Q45854225 | Identification of amino acids in the V3 region of gp120 critical for virus neutralization by human HIV-1-specific antibodies |
| Q36781270 | Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins |
| Q93162297 | Identification of rare HIV-1-infected patients with extreme CD4+ T cell decline despite ART-mediated viral suppression |
| Q52590766 | IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis. |
| Q39108760 | Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies. |
| Q37851260 | Immunological features of human immunodeficiency virus disease |
| Q45056043 | Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3 |
| Q91151705 | Improved Cas9 activity by specific modifications of the tracrRNA |
| Q67574213 | Increased expression of IgG Fc receptor type I on neutrophils and monocytes from HIV-infected subjects |
| Q37592654 | Indian Long-term Non-Progressors Show Broad ADCC Responses with Preferential Recognition of V3 Region of Envelope and a Region from Tat Protein |
| Q34171623 | Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160 |
| Q64263004 | Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1 |
| Q40940339 | Longitudinal study of antibody reactivity against HIV-1 envelope and a peptide representing a conserved site on Gp41 in HIV-1-infected patients. |
| Q38636828 | Multiple cytotoxic effector cells are induced by infection with the human immunodeficiency virus |
| Q40052007 | Natural Killer (NK) Cell Education Differentially Influences HIV Antibody-Dependent NK Cell Activation and Antibody-Dependent Cellular Cytotoxicity |
| Q89548775 | Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization |
| Q35208657 | Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination |
| Q40785849 | Prophylaxis of HIV infection following occupational exposure |
| Q45872516 | Quantitation of antigen-specific immune responses in human immunodeficiency virus (HIV)-infected individuals by limiting dilution analysis |
| Q27330487 | Slow turnover of HIV-1 receptors on quiescent CD4+ T cells causes prolonged surface retention of gp120 immune complexes in vivo |
| Q47604797 | Targeting the Late Stage of HIV-1 Entry for Antibody-Dependent Cellular Cytotoxicity: Structural Basis for Env Epitopes in the C11 Region. |
| Q38366893 | The immunopathogenesis of HIV infection |
| Q61448102 | VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120 |
| Q40205433 | Variability at the FCGR locus: characterization in Black South Africans and evidence for ethnic variation in and out of Africa. |
| Q47564080 | eCD4-Ig promotes ADCC activity of sera from HIV-1-infected patients |
| Q52624996 | eCD4-Ig variants that more potently neutralize HIV-1. |
Search more.